|

Single-cell Multiomics and Spatiotemporal Omics Analyze the Mechanism of Liver Degenerative Disease

RECRUITINGSponsored by Nanfang Hospital, Southern Medical University
Actively Recruiting
SponsorNanfang Hospital, Southern Medical University
Started2023-03-01
Est. completion2025-12-31
Eligibility
Healthy vol.Accepted

Summary

The purpose of this observational study is to employ single-cell multi-omics and spatial omics technologies to characterize the spatial and immune structures within the livers of patients with fatty liver, hepatic hemangioma, focal nodular hyperplasia, liver fibrosis, cirrhosis, and HBV infection. The primary questions it aims to address are: Investigate the mechanisms of liver degenerative changes during the processes of liver aging, fatty liver, HBV infection, liver fibrosis, and cirrhosis. Characterize the molecular features and cellular networks at different stages of liver degeneration and identify new targets and mechanisms for the cure of the aforementioned diseases. The study will collect peripheral blood and discarded liver tissue from patients with hepatic hemangioma, fatty liver, HBV infection, liver fibrosis, and cirrhosis who are undergoing hepatectomy or liver biopsy.

Eligibility

Healthy volunteers accepted
Inclusion Criteria:

1. Voluntarily signed the informed consent form;
2. No restrictions on age and gender;
3. Patients diagnosed with hepatic hemangioma or focal nodular hyperplasia of the liver in accordance with the "Guidelines for the Diagnosis and Treatment of Focal Liver Lesions (2014 Edition)" and the "Guidelines for the Diagnosis and Treatment of Hemangiomas and Vascular Malformations (2019 Edition)";
4. Patients with hepatic hemangioma, focal nodular hyperplasia of the liver, fatty liver, HBV infection, liver fibrosis, and cirrhosis who clinically require liver surgery or liver biopsy.

Exclusion Criteria:

1. Individuals with concurrent infections such as HIV will be excluded.
2. Patients with coagulation system disorders, such as hemophilia or idiopathic thrombocytopenic purpura, will not be included.
3. Those with severe underlying diseases that affect the body's immune status will be excluded.
4. Individuals whom the investigator deems unsuitable for participation in this study will be excluded.

Conditions7

CancerHBV InfectionLiver CancerLiver DiseaseLiver FibrosisLiver NeoplasmNon-alcoholic Fatty Liver Disease NAFLD

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.